NeOnc Adjusts NEO212 Development Plan After FDA Feedback on Capsule-to-Tablet Transition — NeOnc Technologies Holdings, Inc.

Event summary

NeOnc received written FDA feedback on NEO212's CMC development and capsule-to-tablet transition, canceling a scheduled Type B meeting.
FDA deemed NeOnc’s proposed approach reasonable but requested additional comparative assessments if manufacturing processes change.
The agency advised that the tablet formulation transition requires an in vivo relative bioavailability study and completion of key CMC work before late-stage clinical trials.
NeOnc is incorporating FDA feedback into its development plan, with updated timelines and costs expected after assessment.

The big picture

NeOnc’s FDA feedback highlights the regulatory hurdles in transitioning from capsule to tablet formulations, a critical step for late-stage clinical trials. The company’s ability to navigate these requirements will determine NEO212’s path toward potential approval as a treatment for malignant brain tumors and other CNS cancers.

What we're watching

Regulatory Alignment: How NeOnc’s ability to integrate FDA feedback will impact NEO212’s development timeline and costs.
Manufacturing Execution: Whether the company can efficiently finalize tablet formulation, manufacturing processes, and stability studies before late-stage trials.
Clinical Strategy: The pace at which NeOnc advances NEO212 through parallel drug-product development and late-stage clinical programs.